Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness. The company said an independent monitoring committee recommended stopping the study. It concluded that figitumumab in conjunction with Tarceva ...

Biotechnology company Affymax Inc. has received a $5 million milestone payment from Takeda Pharmaceutical Co. for the development of a potential anemia treatment. Affymax said Wednesday that Takeda issued the payment for the startup of late-stage clinical testing of drug Hematide as a treatment for anemia in chronic renal ...

Development-stage drug developer Anadys Pharmaceuticals Inc. said late Wednesday its developing hepatitis C drug was only slightly more effective at treating the virus than placebo in a midstage study. The company's shares plunged 46 cents, or 20 percent, to $1.85 in premarket trading. After 12 ...